XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)

Summary

Our study aims to compare the efficacy and safety of 4-month versus 6-month adjuvant chemotherapy with capecitabine and oxaliplatin following D2 gastrectomy in patients with gastric cancer. Hypothesis: In patients with gastric cancer who have undergone D2 gastrectomy, a 4-month regimen of capecitabine and oxaliplatin demonstrates noninferiority to a 6-month regimen in terms of disease-free survival (DFS) and safety.

Timeline

Start

2017-11-17

Primary completion

2026-07-25

Completion

2026-07-25

Drugs

Indications